Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMZN1A3)

Drug Name
[3H]CGP12177 Drug Info
Synonyms
4-(3-Tert-Butylamino-2-hydroxypropoxy)benzimidazol-2-one; Tbhpbo; 81047-99-6; 4-(3-tert-Butylamino-2-hydroxypropoxy)benzimidazol-2-one; CHEBI:73288; C14H19N3O3; 4-[3-(tert-butylamino)-2-hydroxypropoxy]-1,3-dihydro-2H-benzimidazol-2-one; 4-[3-(tert-butylamino)-2-hydroxypropoxy]-1,3-dihydrobenzimidazol-2-one; 2H-Benzimidazol-2-one, 4-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)-1,3-dihydro-; (+/-)-CGP-12177A hydrochloride; Spectrum_001907; SpecPlus_000776; Spectrum4_000777; AC1Q6M3F
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
2687
ChEBI ID
CHEBI:73288
CAS Number
CAS 81047-99-6
TTD Drug ID
DMZN1A3

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DOT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Adrenergic receptor beta-1 (ADRB1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Propranolol DM79NTF Angina pectoris BA40 Approved [7]
Epinephrine DM3KJBC Acute asthma CA23 Approved [8]
Norepinephrine DMOUC09 Alopecia ED70 Approved [9]
Atenolol DMNKG1Z Angina pectoris BA40 Approved [10]
Acebutolol DM0TI4U Hypertension BA00-BA04 Approved [10]
Metoprolol DMOJ0V6 Acute coronary syndrome BA41 Approved [10]
Timolol DM3NXRU High blood pressure BA00 Approved [11]
Isoproterenol DMK7MEY Atrioventricular block Approved [12]
Betaxolol DM6EUL5 Hypertension BA00-BA04 Approved [13]
Sotalol DML60TN Sinus rhythm disorder BC9Y Approved [14]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Adrenergic receptor beta-3 (ADRB3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Mirabegron DMS1GYT Overactive bladder GC50.0 Approved [15]
Trihexyphenidyl DMB19L8 Dystonia 8A02 Approved [16]
Amosulalol DML8QSZ Hypertension BA00-BA04 Approved [17]
Bopindolol DMIFYLX Hypertension BA00-BA04 Approved [18]
Mepindolol DMUDWP9 Angina pectoris BA40 Approved [19]
Rimiterol DMA47C6 Asthma CA23 Approved [20]
Bitolterol DMK6XAV Chronic obstructive pulmonary disease CA22 Approved [21]
Nipradilol DMA65ER Angina pectoris BA40 Approved [22]
Vibegron DMFR201 Overactive bladder GC50.0 Approved [23]
ONO-2506 DMCA2PJ Stroke 8B20 Phase 2/3 [24]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Adrenergic receptor beta-2 (ADRB2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Indacaterol DMQJHR7 Chronic obstructive pulmonary disease CA22 Approved [25]
Formoterol DMSOURV Allergic asthma CA23.0 Approved [26]
Salbutamol DMN9CWF Acute asthma CA23 Approved [27]
Arformoterol DMYM974 Chronic obstructive pulmonary disease CA22 Approved [28]
Isoproterenol DMK7MEY Atrioventricular block Approved [12]
Salmeterol DMIEU69 Allergic asthma CA23.0 Approved [29]
Clenbuterol DMCKYZ5 Chronic breathing disorder 7A4Z Approved [30]
Ritodrine DM4V6RL Premature labour JB00 Approved [31]
Olodaterol DM62B78 Chronic obstructive pulmonary disease CA22 Approved [32]
Fenoterol DMIP3ZV Asthma CA23 Approved [33]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Beta-3 adrenergic receptor (ADRB3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Rosiglitazone DMILWZR Chronic kidney disease GB61 Approved [34]
Isoproterenol DMK7MEY Atrioventricular block Approved [35]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [36]
Phenylephrine DMZHUO5 Allergic rhinitis CA08.0 Approved [37]
Benzo(a)pyrene DMN7J43 N. A. N. A. Phase 1 [38]
Cyanopindolol DMIBLGH Discovery agent N.A. Investigative [39]
KOJIC ACID DMP84CS Discovery agent N.A. Investigative [40]
[3H]cAMP DMZRQU7 Discovery agent N.A. Investigative [41]
⏷ Show the Full List of 8 Drug(s)
Drug(s) Affected By Beta-2 adrenergic receptor (ADRB2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Salmeterol DMIEU69 Allergic asthma CA23.0 Approved [42]
Bambuterol DMKLSHF Asthma CA23 Approved [43]
Terbutaline DMD4381 Asthma CA23 Approved [44]
Salbutamol DMN9CWF Acute asthma CA23 Approved [45]
Imipramine DM2NUH3 Depression 6A70-6A7Z Approved [46]
Methotrexate DM2TEOL Anterior urethra cancer Approved [47]
Epinephrine DM3KJBC Acute asthma CA23 Approved [48]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [49]
Liothyronine DM6IR3P Congenital hypothyroidism Approved [50]
Ergotidine DM78IME Osteoarthritis FA00-FA05 Approved [51]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Cystic fibrosis transmembrane conductance regulator (CFTR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ivacaftor DMZC1HS Cystic fibrosis CA25 Approved [52]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [53]
Rhucin DM3ADGP Erectile dysfunction HA01.1 Approved [54]
Quercetin DM3NC4M Obesity 5B81 Approved [55]
Miglustat DM5J64S Niemann-Pick disease type C Approved [56]
Glibenclamide DM8JXPZ Diabetic complication 5A2Y Approved [57]
Milrinone DM8TUPF Congestive heart failure BD10 Approved [54]
Oxidized glutathione DM9EQC0 Breast cancer 2C60-2C65 Approved [58]
Glutathione DMAHMT9 Human immunodeficiency virus infection 1C62 Approved [58]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [59]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Mitogen-activated protein kinase 3 (MAPK3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [60]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [61]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [62]
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [63]
Beta-carotene DM0RXBT Vitamin deficiency 5B55-5B71 Approved [64]
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [65]
Secobarbital DM14RF5 Epilepsy 8A60-8A68 Approved [66]
Gefitinib DM15F0X Colon adenocarcinoma Approved [67]
Fexofenadine DM17ONX Allergic rhinitis CA08.0 Approved [68]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [69]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Mitogen-activated protein kinase 1 (MAPK1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ethanol DMDRQZU Chronic pain MG30 Approved [70]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [61]
Carvedilol DMHTEAO Chronic heart failure BD1Z Approved [71]
Paclitaxel DMLB81S Breast carcinoma Approved [72]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [73]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [60]
Urokinase DM0GOUD Myocardial infarction BA41-BA43 Approved [74]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [75]
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [63]
Beta-carotene DM0RXBT Vitamin deficiency 5B55-5B71 Approved [64]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Adrenergic receptor beta-1 (ADRB1) TTR6W5O ADRB1_HUMAN Inhibitor [2]
Adrenergic receptor beta-2 (ADRB2) TT2CJVK ADRB2_HUMAN Inhibitor [2]
Adrenergic receptor beta-3 (ADRB3) TTMXGCW ADRB3_HUMAN Agonist [3]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Beta-2 adrenergic receptor (ADRB2) OTSDOX4Q ADRB2_HUMAN Protein Interaction/Cellular Processes [4]
Beta-3 adrenergic receptor (ADRB3) OTPMG4V7 ADRB3_HUMAN Protein Interaction/Cellular Processes [5]
Cystic fibrosis transmembrane conductance regulator (CFTR) OT6B22QH CFTR_HUMAN Gene/Protein Processing [6]
Mitogen-activated protein kinase 1 (MAPK1) OTH85PI5 MK01_HUMAN Gene/Protein Processing [6]
Mitogen-activated protein kinase 3 (MAPK3) OTCYKGKO MK03_HUMAN Gene/Protein Processing [6]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5387).
2 (4-Piperidin-1-yl)phenyl amides: potent and selective human beta(3) agonists. J Med Chem. 2001 Apr 26;44(9):1456-66.
3 Effects of several putative beta 3-adrenoceptor agonists on lipolysis in human omental adipocytes. Int J Obes Relat Metab Disord. 1996 May;20(5):428-34.
4 Beta 1-adrenoceptor selectivity of nebivolol and bisoprolol. A comparison of [3H]CGP 12.177 and [125I]iodocyanopindolol binding studies. Eur J Pharmacol. 2003 Jan 26;460(1):19-26. doi: 10.1016/s0014-2999(02)02875-3.
5 Synthesis and characterization of high-affinity 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene-labeled fluorescent ligands for human -adrenoceptors. J Med Chem. 2011 Oct 13;54(19):6874-87. doi: 10.1021/jm2008562. Epub 2011 Sep 16.
6 Transfected beta3- but not beta2-adrenergic receptors regulate cystic fibrosis transmembrane conductance regulator activity via a new pathway involving the mitogen-activated protein kinases extracellular signal-regulated kinases. Mol Pharmacol. 2005 Mar;67(3):648-54. doi: 10.1124/mol.104.002097. Epub 2004 Nov 24.
7 Beta-blockers in the treatment of hypertension: are there clinically relevant differences Postgrad Med. 2009 May;121(3):90-8.
8 Adrenergic activation of electrogenic K+ secretion in guinea pig distal colonic epithelium: involvement of beta1- and beta2-adrenergic receptors. Am J Physiol Gastrointest Liver Physiol. 2009 Aug;297(2):G269-77.
9 Impact of exogenous beta-adrenergic receptor stimulation on hepatosplanchnic oxygen kinetics and metabolic activity in septic shock. Crit Care Med. 1999 Feb;27(2):325-31.
10 Prediction and experimental validation of acute toxicity of beta-blockers in Ceriodaphnia dubia. Environ Toxicol Chem. 2005 Oct;24(10):2470-6.
11 Topical dorzolamide 2%/timolol 0.5% ophthalmic solution: a review of its use in the treatment of glaucoma and ocular hypertension. Drugs Aging. 2006;23(12):977-95.
12 Current therapeutic uses and potential of beta-adrenoceptor agonists and antagonists. Eur J Clin Pharmacol. 1998 Feb;53(6):389-404.
13 beta-adrenergic enhancement of brain kynurenic acid production mediated via cAMP-related protein kinase A signaling. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Apr 30;33(3):519-29.
14 beta(2)-adrenoceptors are critical for antidepressant treatment of neuropathic pain. Ann Neurol. 2009 Feb;65(2):218-25.
15 Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
16 Obesity: pathophysiology and clinical management. Curr Med Chem. 2009;16(4):506-21.
17 Effects of amosulalol, a combined alpha 1- and beta-adrenoceptor-blocking agent, on ischemic myocardial energy metabolism in dogs. J Pharm Sci. 1993 Mar;82(3):291-5.
18 Effect of propranolol, alprenolol, pindolol, and bopindolol on beta 2-adrenoceptor density in human lymphocytes. J Cardiovasc Pharmacol. 1986;8 Suppl 6:S70-3.
19 Pharmacological studies on the intrinsic sympathomimetic activity of the beta-adrenoceptor antagonist mepindolol. Arzneimittelforschung. 1986 May;36(5):811-3.
20 Comparison of the beta2-adrenoceptor selectivity of rimiterol, salbutamol and isoprenaline by the intravenous route in man. Br J Clin Pharmacol. 1975 Feb;2(1):41-8.
21 Bitolterol mesylate: a beta-adrenergic agent. Chemistry, pharmacokinetics, pharmacodynamics, adverse effects and clinical efficacy in asthma. Pharmacotherapy. 1985 May-Jun;5(3):127-37.
22 Actions of nipradilol (K-351), a new alpha- and beta-adrenoceptor blocker, on the rabbit portal vein. Jpn J Pharmacol. 1984 Aug;35(4):359-69.
23 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
24 FR149175, a beta 3-adrenoceptor-selective agonist, is a possible therapeutic agent for non-insulin-dependent diabetes mellitus. Jpn J Pharmacol. 1997 May;74(1):109-12.
25 Emerging drugs in chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2009 Mar;14(1):181-94.
26 Long-acting beta2-agonists for chronic obstructive pulmonary disease patients with poorly reversible airflow limitation. Cochrane Database Syst Rev. 2002;(3):CD001104.
27 Potential of beta2-adrenoceptor agonists as add-on therapy for multiple sclerosis: focus on salbutamol (albuterol). CNS Drugs. 2002;16(1):1-8.
28 Arformoterol tartrate in the treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease. Drugs Today (Barc). 2009 Jan;45(1):3-9.
29 Pharmacogenetic tests in asthma therapy. Clin Lab Med. 2008 Dec;28(4):645-65.
30 Postischemic brain injury is attenuated in mice lacking the beta2-adrenergic receptor. Anesth Analg. 2009 Jan;108(1):280-7.
31 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
32 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
33 Functional alpha1- and beta2-adrenergic receptors in human osteoblasts. J Cell Physiol. 2009 Jul;220(1):267-75.
34 Impact of rosiglitazone on the expression of beta3-AR in the stable cell lines expressed beta3-AR gene. Clin Chem Lab Med. 2007;45(11):1511-6. doi: 10.1515/CCLM.2007.315.
35 Discovery of a novel series of biphenyl benzoic acid derivatives as highly potent and selective human beta3 adrenergic receptor agonists with good oral bioavailability. Part II. J Med Chem. 2008 Jul 10;51(13):4002-20. doi: 10.1021/jm8000345. Epub 2008 Jun 14.
36 Blood transcript immune signatures distinguish a subset of people with elevated serum ALT from others given acetaminophen. Clin Pharmacol Ther. 2016 Apr;99(4):432-41.
37 Characterization of beta3-adrenoceptors in human internal mammary artery and putative involvement in coronary artery bypass management. J Am Coll Cardiol. 2005 Jul 19;46(2):351-9. doi: 10.1016/j.jacc.2005.03.061.
38 Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
39 Selective activation of beta3-adrenoceptors by octopamine: comparative studies in mammalian fat cells. Naunyn Schmiedebergs Arch Pharmacol. 1999 Apr;359(4):310-21. doi: 10.1007/pl00005357.
40 Toxicogenomics of kojic acid on gene expression profiling of a375 human malignant melanoma cells. Biol Pharm Bull. 2006 Apr;29(4):655-69.
41 Comparative pharmacology of human beta-adrenergic receptor subtypes--characterization of stably transfected receptors in CHO cells. Naunyn Schmiedebergs Arch Pharmacol. 2004 Feb;369(2):151-9. doi: 10.1007/s00210-003-0860-y. Epub 2004 Jan 17.
42 Pleiotropic beta-agonist-promoted receptor conformations and signals independent of intrinsic activity. Am J Respir Cell Mol Biol. 2007 Feb;36(2):236-43. doi: 10.1165/rcmb.2006-0257OC. Epub 2006 Sep 15.
43 Development of 3D-QSAR models for predicting the activities of chemicals to stimulate muscle growth via (2)-adrenoceptor. Toxicol In Vitro. 2021 Dec;77:105251. doi: 10.1016/j.tiv.2021.105251. Epub 2021 Sep 30.
44 Beta2-adrenergic receptor polymorphisms in African American children with status asthmaticus. Pediatr Crit Care Med. 2006 Jan;7(1):15-8. doi: 10.1097/01.pcc.0000194010.63115.a2.
45 beta2-adrenergic receptor polymorphisms and salbutamol-stimulated energy expenditure. J Clin Endocrinol Metab. 2005 Apr;90(4):2301-7. doi: 10.1210/jc.2004-1356. Epub 2005 Feb 1.
46 Neutrophil beta(2)-adrenoceptor function in major depression: G(s) coupling, effects of imipramine and relationship to treatment outcome. Eur J Pharmacol. 1999 Dec 15;386(2-3):135-44. doi: 10.1016/s0014-2999(99)00749-9.
47 Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthritis Rheumatol. 2014 Jan;66(1):15-23.
48 Myocardial ischaemia and ventricular arrhthymias precipitated by physiological concentrations of adrenaline in patients with coronary artery disease. Br Heart J. 1992 May;67(5):419-20. doi: 10.1136/hrt.67.5.419-b.
49 Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
50 Hormonal regulation of beta2-adrenergic receptor level in prostate cancer. Prostate. 2008 Jul 1;68(10):1133-42. doi: 10.1002/pros.20778.
51 Histamine augments beta2-adrenoceptor-induced cyclic AMP accumulation in human prostate cancer cells DU-145 independently of known histamine receptors. Biochem Pharmacol. 2007 Mar 15;73(6):814-23. doi: 10.1016/j.bcp.2006.11.022. Epub 2006 Dec 1.
52 Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med. 2010 Nov 18;363(21):1991-2003. doi: 10.1056/NEJMoa0909825.
53 Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
54 Adenosine receptors and phosphodiesterase inhibitors stimulate Cl- secretion in Calu-3 cells. Am J Respir Cell Mol Biol. 2003 Sep;29(3 Pt 1):410-8. doi: 10.1165/rcmb.2002-0247OC. Epub 2003 Apr 24.
55 Modulation of deltaF508 cystic fibrosis transmembrane regulator trafficking and function with 4-phenylbutyrate and flavonoids. Am J Respir Cell Mol Biol. 2004 Sep;31(3):351-7. doi: 10.1165/rcmb.2002-0086OC. Epub 2004 Jun 10.
56 Proteasome-dependent pharmacological rescue of cystic fibrosis transmembrane conductance regulator revealed by mutation of glycine 622. J Pharmacol Exp Ther. 2008 Apr;325(1):89-99. doi: 10.1124/jpet.107.134502. Epub 2008 Jan 29.
57 Comparative pharmacology of the activity of wild-type and G551D mutated CFTR chloride channel: effect of the benzimidazolone derivative NS004. J Membr Biol. 2003 Jul 15;194(2):109-17. doi: 10.1007/s00232-003-2030-z.
58 Reversible silencing of CFTR chloride channels by glutathionylation. J Gen Physiol. 2005 Feb;125(2):127-41. doi: 10.1085/jgp.200409115. Epub 2005 Jan 18.
59 Integrative "-Omics" analysis in primary human hepatocytes unravels persistent mechanisms of cyclosporine A-induced cholestasis. Chem Res Toxicol. 2016 Dec 19;29(12):2164-2174.
60 Treatment with anticancer agents induces dysregulation of specific Wnt signaling pathways in human ovarian luteinized granulosa cells in vitro. Toxicol Sci. 2013 Nov;136(1):183-92. doi: 10.1093/toxsci/kft175. Epub 2013 Aug 16.
61 Progesterone increases csk homologous kinase in HMC-1560 human mast cells and reduces cell proliferation. J Cell Biochem. 2007 Dec 1;102(5):1271-80. doi: 10.1002/jcb.21357.
62 Cannabidiol upregulates melanogenesis through CB1 dependent pathway by activating p38 MAPK and p42/44 MAPK. Chem Biol Interact. 2017 Aug 1;273:107-114. doi: 10.1016/j.cbi.2017.06.005. Epub 2017 Jun 7.
63 Sertraline, an antidepressant, induces apoptosis in hepatic cells through the mitogen-activated protein kinase pathway. Toxicol Sci. 2014 Feb;137(2):404-15. doi: 10.1093/toxsci/kft254. Epub 2013 Nov 5.
64 Growth stimulation of human pulmonary adenocarcinoma cells and small airway epithelial cells by beta-carotene via activation of cAMP, PKA, CREB and ERK1/2. Int J Cancer. 2006 Mar 15;118(6):1370-80. doi: 10.1002/ijc.21537.
65 Estrogen and pure antiestrogen fulvestrant (ICI 182 780) augment cell-matrigel adhesion of MCF-7 breast cancer cells through a novel G protein coupled estrogen receptor (GPR30)-to-calpain signaling axis. Toxicol Appl Pharmacol. 2014 Mar 1;275(2):176-81. doi: 10.1016/j.taap.2014.01.005. Epub 2014 Jan 17.
66 Inhibition of activator protein 1 by barbiturates is mediated by differential effects on mitogen-activated protein kinases and the small G proteins ras and rac-1. J Pharmacol Exp Ther. 2004 Dec;311(3):1232-40. doi: 10.1124/jpet.104.071332. Epub 2004 Jul 19.
67 Growth of hormone-dependent MCF-7 breast cancer cells is promoted by constitutive caveolin-1 whose expression is lost in an EGF-R-mediated manner during development of tamoxifen resistance. Breast Cancer Res Treat. 2010 Feb;119(3):575-91. doi: 10.1007/s10549-009-0355-8. Epub 2009 Mar 15.
68 Effect of histamine H1 receptor antagonists on TARC/CCL17 and MDC/CCL22 production from CD14+ cells induced by antigenic stimulation in vitro. Int Arch Allergy Immunol. 2011;155(1):38-51. doi: 10.1159/000318720. Epub 2010 Nov 25.
69 SIRT3 Mediates the Antioxidant Effect of Hydrogen Sulfide in Endothelial Cells. Antioxid Redox Signal. 2016 Feb 20;24(6):329-43. doi: 10.1089/ars.2015.6331. Epub 2015 Nov 10.
70 Downregulation of mitogen-activated protein kinases (MAPKs) in chronic ethanol-induced fatty liver. Toxicol Mech Methods. 2020 Jul;30(6):407-416. doi: 10.1080/15376516.2020.1747126. Epub 2020 Apr 1.
71 A unique mechanism of beta-blocker action: carvedilol stimulates beta-arrestin signaling. Proc Natl Acad Sci U S A. 2007 Oct 16;104(42):16657-62. doi: 10.1073/pnas.0707936104. Epub 2007 Oct 9.
72 The stent-eluting drugs sirolimus and paclitaxel suppress healing of the endothelium by induction of autophagy. Am J Pathol. 2009 Nov;175(5):2226-34.
73 Modulation of apoptosis in HaCaT keratinocytes via differential regulation of ERK signaling pathway by flavonoids. J Biol Chem. 2005 Sep 9;280(36):31498-507. doi: 10.1074/jbc.M505537200. Epub 2005 Jul 13.
74 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
75 Cannabidiol Modulates the Immunophenotype and Inhibits the Activation of the Inflammasome in Human Gingival Mesenchymal Stem Cells. Front Physiol. 2016 Nov 24;7:559. doi: 10.3389/fphys.2016.00559. eCollection 2016.